Skip to main content
. 2016 Dec 5;127(1):383–401. doi: 10.1172/JCI83822

Figure 9. MFG-E8 administration after MI improves cardiac function in vivo.

Figure 9

(A) Schematic representation of MFG-E8 intramyocardial injection. (B) TUNEL-positive nuclei in border zone of PBS- or MFG-E8–administered mice (3.2 μg) (sham, n = 5; MI, n = 7) 3 days after MI. (C) MFG-E8 intramyocardial injection (1.6 or 3.2 μg) decreased expression of the upregulated inflammatory genes at the infarct (Inf), not remote (Rem), areas of hearts 3 days after MI (n = 4 each). (D) Temporal changes in echocardiographic parameters (LV end-diastolic internal diameter [LVIDd], LV end-systolic internal diameter [LVIDs], interventricular-septal thickness at end-diastole [IVSTd], ejection fraction, and fractional shortening) of PBS-treated (sham, n = 7, black-dotted lines; MI, n = 10, black lines) or MFG-E8–treated mice (sham, n = 7, red-dotted lines; MI; n = 7, red lines) 2, 6, 8, and 10 weeks after MI. (E) Hemodynamic parameters (dP/dtmax, -dP/dtmin, and Tau) of PBS-treated (sham, n = 3; MI, n = 7) or MFG-E8–treated mice (sham, n = 5; MI, n = 7) 10 weeks after MI. (F) Heart weight to body weight ratio of PBS-treated (sham, n = 7; MI, n = 10) or MFG-E8–treated mice (sham, n = 7; MI, n = 9) 10 weeks after MI. (G) Representative Masson’s trichrome–stained heart sections of PBS-administered (n = 6) or MFG-E8–administered mice (n = 5) 10 weeks after MI. Scale bars: 1 mm. Error bars represent the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA followed by Newman-Keuls analysis.